A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

NCT02583594 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Multiple Sclerosis

Interventions

DRUG: Acyclovir
DRUG: Methylprednisolone
DRUG: alemtuzumab GZ402673
DRUG: alemtuzumab GZ402673
DRUG: Paracetamol
DRUG: Loratadine
DRUG: Ceterizine
DRUG: Dexchlorpheniramine

Sponsor

Genzyme, a Sanofi Company